Distribution of Predicted Nivolumab Exposures at 480 mg Q4W for Adult ADA+ and ADA- Patients Treated with Relatlimab Plus Nivolumab
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: